Potential antivirals and antiviral strategies against SARS coronavirus infections

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 2, 2006, Pages 291-302

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Coronavirus; Interferon; Monoclonal antibody; Protease inhibitors; S protein; SARS; SARS CoV inhibitors; siRNA

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; AURINTRICARBOXYLIC ACID; BETA INTERFERON; CALPASTATIN; CELL RECEPTOR; CHLOROQUINE; CINANSERIN; CONSENSUS INTERFERON; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; ENFUVIRTIDE; EREMOMYCIN; GLYCYRRHIZA EXTRACT; GLYCYRRHIZIC ACID; HESPERETIN; ISATIS INDIGOTICA EXTRACT; MONOCLONAL ANTIBODY; NELFINAVIR; NICLOSAMIDE; PLANT EXTRACT; PLANT LECTIN; POLYPEPTIDE ANTIBIOTIC AGENT; RNA DIRECTED RNA POLYMERASE; SMALL INTERFERING RNA; TEICOPLANIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINOMYCIN; VANCOMYCIN; VIRUS GLYCOPROTEIN;

ANTIVIRAL ACTIVITY; CELL MEMBRANE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPROPHYLAXIS; IN VITRO STUDY; INHIBITION KINETICS; MEMBRANE FUSION; PATHOGENESIS; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN PROCESSING; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 33646166978     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.2.291     Document Type: Review

References (94)

1. Peiris JS, Lai ST, Poon LL et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-1325 (2003).
2. Lee N, Hui D, Wu A et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1986-1994 (2003).
3. Ksiazek TG, Erdman D, Goldsmith CS et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953-1966 (2003).
4. Drosten C, Gunther S, Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967-1976 (2003).
5. Kuiken T, Fouchier RA, Schutten M et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362, 263-270 (2003).
6. Fouchier RA, Kuiken T, Schutten M et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423, 240 (2003).
7. van der Hoek L, Pyrc K, Jebbink MF et al. Identification of a new human coronavirus. Nature Med. 10, 368-373 (2004).
8. Stadler K, Masignani V, Eickmann M et al. SARS - beginning to understand a new virus. Nature Rev. Microbial. 1, 209-218 (2003).
9. Oxford A Balasingam S, Chan C, Catchpole A, Lambkin R. New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus. Antiviral Chem. Chemother. 16, 13-21 (2005).
10. Shigeta S, Yamase T. Current status of anti-SARS agents. Antiviral Chem. Chemother. 16, 23-32 (2005).
11. De Clercq E. Antivirals and antiviral strategies. Nature Rev. Microbial. 2, 704-720 (2004).
12. Li W, Moore MJ, Vasilleva. N et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450-454 (2003).
13. Hofmann H, Geier M, Marzi A et al. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem. Biophys. Res. Commun. 319, 1216-1221 (2004).
14. Jia HP, Look DC, Shi L et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J. Virol. 79, 14614-14621 (2005).
15. Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279, 3197-3201 (2004).
16. Sul J, Li W, Murakami A et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl Acad. Sci. USA 101, 2536-2541 (2004).
17. Towler P, Staker B, Prasad SG et al. ACE2 X-ray structures reveal a large hingebending motion important for inhibitor binding and catalysis. J. Biol. Chem. 279, 17996-18007 (2004).
18. Tripet B, Howard MW, Jobling M, Holmes RK, Holmes KV, Hodges RS. Structural characterization of the SARS-coronavirus spike S fusion protein core. J. Biol. Chem. 279, 20836-20849 (2004).
19. Liu S, Xiao G, Chen Y et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363, 938-947 (2004).
20. Zhu J, Xiao G, Xu Y et al. Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem. Biophys. Res. Commun. 319, 283-288 (2004).
21. Ni L, Zhu J, Zhang J, Yan M, Gao GF, Tien P. Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain. Biochem. Biophys. Res. Commun. 330, 39-45 (2005).
22. Veiga S, Yuan Y, Li X et al. Why are HIV-1 fusion inhibitors not effective against SARS-CoV? Biophysical evaluation of molecular interactions. Biochim. Biophys. Acta 1760, 55-61 (2006).
23. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry, Proc. Natl Acad. Sci. USA 102, 11876-11881 (2005).
24. Barnard DL, Hubbard VD, Burton J et al. Inhibition of severe acute respiratory syndrome-associated coronavirus; (SARSCoV) by calpain inhibitors and β-D-N4-hydroxycytidine. Antiviral Chem. Chemother. 15, 15-22 (2004).
25. Anand K, Ziebuhr J. Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300, 1763-1767 (2003).
26. Chou KC, Wei DQ, Zhong WZ. Binding mechanisms of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem. Biophys. Res. Commun. 308, 148-151 (2003).
27. Yang H, Yang M, Ding Y et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl Acad. Sci. USA 100, 13190-13195 (2003).
28. Lee T-W, Cherney MM, Huitema C et al. Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. J. Mol. Biol. 353, 1137-1151 (2005).
29. Fan K, Wei P, Feng Q et al. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J. Biol. Cbem.279, 1637-1642 (2004).
30. Martina E, Stiefl N, Degel B et al. Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor. Bioorg. Med. Chem. Lett. 15, 5365-5369 (2005).
31. Jain RP, Pettersson HI, Zhang J et al. Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. J. Med. Chem. 47, 6113-6116 (2004).
32. Ghosh AK, Xi K, Ratia K et al. Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. J. Med. Chem. 48, 6767-6771 (2005).
33. Shie J-J, Fang J-M, Kuo C-J et al. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. J. Med. Chem. 48, 4469-4473 (2005).
34. Kaeppler U, Stiefl N, Schiller M et al. A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods. J. Med. Chem. 48, 6832-6842 (2005).
35. Chen L-R, Wang Y-C, Lin YW et al. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. Bioorg. Med, Chem. Lett. 15, 3058-3062 (2005).
36. Liu Y-C, Huang V, Chao T-C et al. Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease. Biochem. Biophys. Res. Commun. 333, 194-199 (2005).
37. Chen C-N, Lin CPC, Huang K-K et al. Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3,3′-digallate (TF3). Evid. Based Complement Alternat Med. 2, 209-215 (2005).
38. Shie J-J, Fang J-M, Kuo T-H et al. Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic α,β-unsaturated esters. Bioorg. Med. Chem. 13, 5240-5252 (2005).
39. Chen L, Gui C, Luo X et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro, J. Virol. 79, 7095-7103 (2005).
40. Gan Y-R, Huang H, Huang Y-D et al. Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase. Peptides (2005) (Epub ahead of print).
41. Barretto N, Jukneliene D, Ratia K, Chen Z, Mesecar AD, Baker SC. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J. Virol. 79, 15189-15198 (2005).
42. Lindner HA, Fotouhi-Ardakani N, Lytvyn V, Lachance P, Sulea T, Ménard R. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J. Virol. 79, 15199-15208 (2005).
43. Tanner JA, Watt RM, Chai YB et al. The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5′ to 3′ viral helicases. J. Biol. Chem. 278, 39578-39582 (2003).
44. Tanner JA, Zheng B-J, Zhou J et al. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem. Biol. 12, 303-311 (2005).
45. Xu X, Liu Y, Weiss S, Arnold E, Sarafianos SG, Ding J. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res. 31, 7117-7130 (2003).
46. Cheng A, Zhang W, Xie Y et al. Expression, purification, and characterization of SARS coronavirus RNA polymerase. Virology 335, 165-176 (2005).
47. Guarino LA, Bhardwaj K, Dong W, Sun J, Holzenburg A, Kao C. Mutational analysis of the SARS virus Nsp 15 endoribonuclease: identification of residues affecting hexamer formation. J. Mol. Biol. 353, 1106-1117 (2005).
48. Sui J. Li W, Roberts A et al. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J. Virol. 79, 5900-5906 (2005).
49. ter Meulen J, Bakker ABH, van den Brink EN et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363, 2139-2141 (2004).
50. Subbarao K, McAuliffe J, Vogel L et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J. Virol. 78, 3572-3577 (2004).
51. Zhang L, Zhang F, Yu W et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J. Med. Virol. 78, 1-8 (2006).
52. Wong VWS, Dai D, Wu AKL, Sung JJY. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med. J. 9, 199-201 (2003).
53. Baizarini J, Van Laethem K, Hatse S et al. Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV gp120. A new therapeutic concept to hit the Achilles heel of HIV. J. Biol. Chem. 280, 41005-41014 (2005).
54. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet 362, 293-294 (2003).
55. Hensley LE, Fritz EA, Jahrling PB, Karp CL, Huggins JW, Geisberg TW. Interferon-β la and SARS coronavirus replication. Emerg. Infect. Dis. 10, 317-319 (2004).
56. Ströher U, DiCaro A, Li Y et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. J. Infect. Dis. 189, 1164-1167 (2004).
57. Zheng B, He M-L, Wong K-L et al. Potent inhibition of SARS-associated coronavirus (SCoV) infection and replication by type I interferons (IFN-α/β) but not by type II interferon (IFN-γ). J Interferon Cytokine Res. 24, 388-390 (2004).
58. Spiegel M, Pichlmair A, Mühlberger E, Haller O, Weber F. The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein. J. Clin. Virol. 30, 211-213 (2004).
59. Sainz B Jr, Mossel EC, Peters CJ, Garry RF. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 329, 11-17 (2004).
60. Loutfy MR, Blatt LM, Siminovitch KA et al. Interferon alfacon- 1 plus corticosteroids in severe acute respiratory syndrome. JAMA 290, 3222-3228 (2003).
61. Bao M, Zhang Y, Wan M et al. Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide. Clin. Immunol. 118(2-3), 180-187 (2006).
62. Haagmans BL, Kuiken T, Martina BE et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nature Med. 10, 290-293 (2004).
63. Stevenson M. Therapeutic potential of RNA interference. N. Engl. J. Med. 351, 1772-1777 (2004).
64. He M-L, Zheng B, Peng Y et al. Inhibition of SARS-associated coronavirus infection and replication by RNA interference. JAMA 290, 2665-2666 (2003).
65. Zhang Y, Li T, Fu L et al. Silencing SARS-CoV spike protein expression in cultured cells by RNA interference. FEBS Lett. 560, 141-146 (2004).
66. Li B-j, Tang Q, Cheng D et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque. Nature Med. 11, 944-951 (2005).
67. Chang Z, Hu J. RNAi therapeutics: can siRNAs conquer SARS? Gene Ther. (2005) (Epub ahead of print).
68. Neuman BW, Stein DA, Kroeker AD et al. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J. Virol, 79, 9665-9676 (2005).
69. Wu C-Y, Jan J-T, Ma S-H et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl Acad. Sci. USA 101, 10012-10017 (2004).
70. Balzarini J, Keyaerts E, Vijgen L, De Clercq E, Preobrazhenskaya M, Van Ranst M. Inhibitory activity of vancomycin, eremomycin and teicoplanin aglycon derivatives against feline and human coronaviruses (i.e. SARS). 17th International Conference an Antiviral Research. AZ, USA, 2-6 May 2004. Antiviral Res. 62(A59), 78 (2004).
71. Balzarini J, Vijgen L, Keyaerts E et al, Mannose-specific plant lectins are potent inhibitors of coronavirus infection including the virus causing SARS. l7th International Conference on Antiviral Research. AZ, USA, 2-6 May 2004. Antiviral Res. 62(A76), 122 (2004).
72. Vijgen L, Keyaerts E, Van Damme E et al. Antiviral effect of plant compounds of the Alliaceae family against the SARS coronavirus. 17th International Conference on Antiviral Research. AZ, USA, 2-6 May 2004. Antiviral Res. 62(A76), 123 (2004).
73. Lin C-W, Tsai F-J, Tsai C-H et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 68, 36-42 (2005).
74. Ito M, Nakashima H, Baba M et al. Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)]. Antiviral Res. 7, 127-137 (1987).
75. Ito M, Sato A, Hirabayashi K et al. Mechanism of inhibitory effect of glycyrrhizin on replication human immunodeficiency virus (HIV). Antiviral Res. 10, 289-298 (1988).
76. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW, Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361, 2045-2046 (2003).
77. Hoever G, Baltina L, Michaelis M et al. Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. J. Med. Chem. 48, 1256-1259 (2005).
78. He R, Adonov A, Traykova-Adonova M et al. Potent and selective inhibition of SARS coronavirus replicatoin by aurintricarboxylic acid. Biochem. Biophys. Res. Commun. 320, 1199-1203 (2004).
79. Ya YL, Zhang XW, Andonov A, He RT. Structural analysis of inhibition mechanisms of aurintricarboxylic acid on SARS-CoV polymerase and other proteins. Comp. Biol. Chem. 29, 212-219 (2005).
80. Cushman M, Wang P, Chang SH et al. Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight. J. Med. Chem. 34, 329-337 (1991).
81. Cushman M, Kanamathareddy S, De Clercq E, Schols D, Goldman ME, Bowen JA. Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds. J. Med. Chem. 34, 337-342 (1991).
82. Balzarini J, Mitsuya H, De Clercq E, Broder S. Aurintricarboxylic acid and Evans blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. Biochem. Biophys. Res. Commun. 136, 64-71 (1986).
83. Schols D, Baba M, Pauwels R, Desmyter J, De Clercq E. Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor. Proc. Natl/Acad. Sci. USA 86, 3322-3326 (1989).
84. Sidwell RW, Huffman JH, Khare GP Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177, 705-706 (1972).
85. Streeter DG, Witkowski JT, Khare GP et al. Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole), a new broadspectrum antiviral agent. Proc. Natl/Acad. Sci. USA 70, 1174-1178 (1973).
86. Saijo M, Morikawa S, Fukushi S et al. Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus. Antiviral Res. 66, 159-163 (2005).
87. Savarino, A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect. Dis. 3, 722-727 (2003).
88. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun. 323, 264-268 (2004).
89. Vincent MJ, Bergeron E, Benjannet S et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2, 69 (2005).
90. Keyaerts E, Vijgen L, Chen L, Maes P, Hedenstierna G, Van Ranst M. Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound. Int. J. Infect. Dis. 8, 223-226 (2004).
91. Wu C-J, Jan J-T, Chen C-M et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob. Agents Chemother. 48, 2693-2696 (2004).
92. Yamamoto N, Yang R, Yoshinaka Y et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem. Biophys. Res. Commun. 318, 719-725 (2004).
93. Chu CM, Cheng VCC, Hung IFN et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59, 252-256 (2004).
94. Chan KS, Lai ST, Chu CM et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med. J. 9, 399-406 (2003).